Library Open Repository
Belimumab (Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline)
Ding, C and Jones, G (2006) Belimumab (Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline). Current Opinion in Investigational Drugs, 7 (5). pp. 464-472. ISSN 1472-4472
belimumab.pdf | Request a copy
Full text restricted
Available under University of Tasmania Standard License.
Belimumab, the lead in a series of human monoclonal antibodies against the human protein B-lymphocyte stimulator (BLyS), is under development by Human Genome Sciences, Cambridge Antibody Technology and GlaxoSmithKline for the potential treatment of autoimmune diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). By January 2006, belimumab had completed phase II clinical trials in SLE and RA; a phase III clinical SLE trial is scheduled to begin later this year.
|Journal or Publication Title:||Current Opinion in Investigational Drugs|
|Page Range:||pp. 464-472|
|Additional Information:||restricted - published by Thompson|
|Date Deposited:||07 Apr 2008 01:36|
|Last Modified:||18 Nov 2014 03:32|
|Item Statistics:||View statistics for this item|
Actions (login required)
|Item Control Page|